Management of COPD in Vietnam during the COVID-19 period: Current situation and challenges.

Publication date: Feb 07, 2025

To evaluate the changes in exacerbation rates and other clinical outcomes, and identify remaining difficulties in the management of chronic obstructive pulmonary disease (COPD) at Vietnamese COPD management units (CMUs). A multi-center, prospective cohort study was conducted on COPD at the CMUs of 3 study sites. COPD exacerbation was the primary outcome of this study. Demographic and clinical informations were collected at study entry. Participants were followed-up for 12-15 months from the study inclusion. Over the follow-up period, reduction was observed in the prevalence of patients with hospitalization (decreased from 42. 3% to 34. 4%) and ICU/ED admission (decreased from 5. 7% to 0. 6%). The annual exacerbation rate and hospitalization rate were 0. 75+/-0. 89 and 0. 56+/-0. 70, respectively. The severity of symptoms, degree of airflow obstruction, and BMI were factors associated with increased frequency of COPD exacerbations and associated with increased annual exacerbation rate. Our results highlight the difficulties and challenges in managing COPD during the COVID-19 epidemic, including increasing numbers of smokers, inadequate testing request rates, and prescribing medication inconsistent with standard treatment guidelines. Our results highlight the difficulties and challenges in managing COPD during the COVID-19 epidemic, including increasing numbers of smokers, inadequate testing request rates, and prescribing medication inconsistent with standard treatment guidelines. These findings provide a foundation for future interventions and policy improvements.

Open Access PDF

Concepts Keywords
Annual challenges
Exacerbation CMU
Hospitalization COPD
Seoul COVID
Vietnamese management

Semantics

Type Source Name
disease MESH COPD
disease MESH COVID-19
pathway REACTOME Disease
disease IDO disease
disease MESH chronic condition
drug DRUGBANK Medical air
disease IDO intervention
disease IDO symptom
disease IDO blood
disease MESH respiratory diseases
disease MESH influenza
disease MESH pneumococcal infections
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH bronchiectasis
disease MESH lung cancer
disease MESH pneumonia
disease MESH bronchitis
drug DRUGBANK Gold
disease MESH emergency
disease MESH causes
disease MESH respiratory failure
disease IDO facility
drug DRUGBANK Methionine
disease IDO history
disease MESH dyspnea
disease IDO process
disease MESH privacy
disease MESH Hypertension
disease MESH comorbidity
disease MESH GERD
disease MESH underweight
disease MESH overweight
disease MESH airway obstruction
drug DRUGBANK Spinosad
drug DRUGBANK Nicotine
drug DRUGBANK Etoperidone
disease MESH cardiovascular diseases
disease MESH complications
disease MESH missed diagnoses
disease MESH pleural diseases
disease MESH pulmonary fibrosis
drug DRUGBANK Amlodipine
disease IDO country
disease MESH asthma
pathway KEGG Asthma
disease MESH Clinical Relevance
drug DRUGBANK Varenicline
drug DRUGBANK Bupropion
drug DRUGBANK Nortriptyline
disease MESH obstructive lung diseases
disease MESH Allergy

Original Article

(Visited 4 times, 1 visits today)